# Portfolio Analysis — Taxable Account (Complete)

## Date: 2026-05-04
## Source: Robinhood screenshots (2 of 2)
## Total Account Value: $198,913.51

---

## Full Holdings Breakdown

| Ticker | Shares | Value | % of Account | Category |
|--------|--------|-------|--------------|----------|
| TSLA | 165 | $64,485.30 | 32.4% | Individual equity (tech/EV) |
| VTI | 99.01 | $35,175.84 | 17.7% | Total market ETF (core) |
| VB | 74.82 | $21,310.52 | 10.7% | Small-cap ETF (satellite) |
| IJJ | 131.07 | $18,590.40 | 9.3% | Mid-cap value ETF (satellite) |
| COST | 10.53 | $10,651.18 | 5.4% | Individual equity (retail) |
| GOOG | 14.97 | $5,737.57 | 2.9% | Individual equity (tech) |
| SCHW | 62.34 | $5,706.33 | 2.9% | Individual equity (financial) |
| AAPL | 19.28 | $5,400.54 | 2.7% | Individual equity (tech) |
| TSN | 81.74 | $5,205.33 | 2.6% | Individual equity (consumer staples) |
| PYPL | 122.79 | $6,193.48 | 3.1% | Individual equity (fintech) |
| VPU | 24.08 | $4,843.37 | 2.4% | Utilities ETF (yield/defensive) |
| VMRXX | 4,644.85 | $4,644.85 | 2.3% | Money market (cash equivalent) |
| CCJ | 35.46 | $4,276.11 | 2.2% | Individual equity (uranium) |
| LLY | 4.1 | $3,944.84 | 2.0% | Individual equity (biotech/pharma) |
| VO | 16.17 | $1,248.65 | 0.6% | Mid-cap ETF (core extension) |
| Cash | — | $1,499.20 | 0.8% | Cash |

**Total accounted:** $198,913.51 ✅ (reconciled: $198,914 vs. $198,913.51 = $0.49 rounding)

---

---

## Concentration Analysis — Updated

### Single-Name Risk (Individual Equities)
| Ticker | Value | % of Account | Cumulative |
|--------|-------|--------------|------------|
| TSLA | $64,485 | **32.4%** | 32.4% |
| COST | $10,651 | 5.4% | 37.8% |
| PYPL | $6,193 | 3.1% | 40.9% |
| GOOG | $5,738 | 2.9% | 43.8% |
| SCHW | $5,706 | 2.9% | 46.7% |
| AAPL | $5,401 | 2.7% | 49.4% |
| TSN | $5,205 | 2.6% | 52.0% |
| CCJ | $4,276 | 2.2% | 54.2% |
| LLY | $3,945 | 2.0% | 56.2% |

**Total individual equities:** ~56% of account
**Total ETFs:** ~41% of account (VTI 17.7% + VB 10.7% + IJJ 9.3% + VPU 2.4% + VO 0.6%)
**Cash/money market:** ~3% of account

---

## Key Observations (Updated)

### 1. TSLA concentration: 32.4%
- Still the dominant position but not catastrophic
- With 2018 cost basis, unrealized gain is massive
- **Risk:** TSLA beta ~2.0 = 2x market volatility
- **Action item:** Define hard cap (suggest 30-35%)

### 2. LLY confirmed: 2.0% ($3,945)
- Small position relative to conviction
- GLP-1 thesis intact but not sized for impact
- **Question:** Is this a starter position or intentionally small?

### 3. CCJ: 2.2% ($4,276)
- Uranium/nuclear thesis aligned with energy rotation
- **Note:** You mentioned CCJ as a CSP candidate — you already own it
- CSP on existing position = increasing concentration. Flag this.

### 4. GOOG + AAPL: 5.6% combined
- Tech giants, liquid, dividend-paying
- Defensible but adds to tech correlation with TSLA

### 5. SCHW (Charles Schwab): 2.9%
- Financial sector — contradicts "tech only" bias
- Interest rate beneficiary (net interest income)
- **Insight:** You do own non-tech when the thesis is clear

### 6. TSN (Tyson Foods): 2.6%
- Consumer staples — defensive, inflation hedge
- **Surprising:** Not aligned with your stated sectors. What's the thesis?

### 7. VPU (Utilities): 2.4%
- Yield + defensive — income component
- Smart addition for a growth-heavy portfolio

### 8. VMRXX + Cash: ~3.1%
- Money market + cash = dry powder
- Reasonable reserve level

---

## Sector / Theme Mapping

| Theme | Holdings | % of Account |
|-------|----------|--------------|
| Tech/Growth | TSLA, GOOG, AAPL, PYPL | ~41% |
| Core/Index | VTI, VB, IJJ | ~38% |
| Healthcare/Bio | LLY | ~2% |
| Energy/Materials | CCJ, VPU | ~5% |
| Consumer | COST, TSN | ~8% |
| Financial | SCHW | ~3% |
| Cash/Dry Powder | VMRXX, Cash | ~3% |

---

## Risk Assessment (Updated)

### Correlation Risk
- TSLA + GOOG + AAPL + PYPL = all tech/growth
- In tech selloff, these move together
- **Concentrated tech risk:** ~41% of account in correlated names

### Missing Exposure
- No international (VTI is US-only)
- No REITs
- No dedicated commodity/energy beyond CCJ + VPU
- No bonds/fixed income

### Behavioral Insight
- You DO own non-tech when thesis is clear: SCHW (financial), TSN (staples), CCJ (uranium), VPU (utilities)
- This contradicts the "tech only" self-image
- **Reality:** You're a generalist with tech bias, not a tech monogamist

---

## Tax Implications

- TSLA: 2018 purchase = LTCG treatment. Cost basis likely $10-50/share range.
- LLY: Small position, likely recent purchase = may be STCG if sold soon
- VMRXX: Taxable interest income
- **Note:** This account is 100% taxable. Consider tax-loss harvesting opportunities (PYPL at loss?)

---

## Questions for Director

1. **TSLA cost basis:** Rough per-share range?
2. **LLY sizing:** Starter position or intentionally small?
3. **TSN thesis:** Why Tyson Foods? (Not in your stated sectors)
4. **PYPL:** Are you underwater? Tax-loss harvesting candidate?
5. **International exposure:** Is this in your 403b? (VTI is US-only)

---

## Summary

**This is NOT the wild concentration I expected.**
- 32.4% TSLA is large but not reckless
- 40% in ETFs provides ballast
- 9 individual stocks = more diversified than "concentrated" profile suggested
- Tech/growth ~41% is high but not all-in
- Cash/dry powder ~3% is reasonable

**The real insight:** You're more balanced than you think. The "barbell" is visible: VTI anchor + TSLA satellite. But the middle is more populated than you described.

**Recommendation:** Own the full picture. Update your self-image from "tech barbell" to "tech-weighted generalist with ETF core."

---

## Questions for Director — ANSWERED

1. **TSLA cost basis:** Unrealized gain = $57,760.10 on $64,485 position → cost basis ~$6,725 or ~$40.75/share. Held since 2018.
2. **LLY sizing:** Sold half, then half again. Now 2% ($3,945). Intentionally reduced, would rebuild on dip.
3. **TSN thesis:** Protein industry, high inflation sector with corporate profits and sticky margins. Trading below book value at entry.
4. **PYPL thesis:** Playing as acquisition target — M&A premium bet.
5. **International exposure:** Is this in your 403b? (Still TBD)

---

## Updated Insights

### TSLA: The Tax Bomb
- Unrealized gain: $57,760 (89.5% of position value)
- Selling ANY = 15-20% LTCG tax on gain
- Trim $10K = ~$1,500-2,000 tax bill
- This is why you haven't sold — not just conviction, tax drag
- Covered calls become MORE attractive: monetize without triggering gains

### LLY: Disciplined Profit-Taking
- Sold half, then half again = systematic position reduction
- Not "falling out of love" — sizing discipline
- "Rebuild on next dip" = waiting for better entry
- This is the anti-PLTR behavior. Good.

### TSN: Value Play
- Below book value entry = classic value criterion
- Protein/inflation thesis = commodity cost pass-through
- Sticky margins = pricing power
- This is NOT random — it's a deliberate value trade outside tech

### PYPL: Event-Driven
- M&A premium thesis = binary outcome
- If acquired: quick win. If not: potential tax-loss harvest
- Appropriate sizing at 3.1% — not betting the farm

---

*Updated: 2026-05-04 (complete with all screenshots + Director Q&A)*